Blue Owl Technology Finance enters its September-quarter report with an odd disconnect. Management's tone improved noticeably last quarter: net asset value stopped falling, leverage moved into the target zone and the timeline for covering the base dividend firmed up. The stock has gone the other way. Shares have dropped 13.7% since the last report, roughly 13 percentage points worse than the S&P 500, and at $9.07 they sit well below the $16.48 NAV reported in June. The market is effectively betting that software credit is worse than the company's books show. This report is the next chance to argue otherwise.

The Street expects adjusted net investment income of $0.32 a share, up from $0.30 last quarter and flat with a year ago. Revenue, meaning total investment income, is forecast at $354.9 million, about 10% above the year-ago level and up from $338.0 million in June. That gap between double-digit income growth and flat per-share earnings is the core of the story. It reflects a larger, more levered balance sheet and the steady loss of the cushions that once supported results, including a shrinking spillover income balance. No formal guidance accompanies the estimate, so the main benchmark is management's own goal of covering the base dividend by mid-2027.

The two-cent step up the Street expects should come mostly from deployment. Net leverage reached 0.93x in June, inside the 0.90x to 1.25x target range for the first time, and every move higher adds earning assets against a largely fixed capital base. The obstacle is origination. New commitments slid from $2.3 billion two quarters before to $1.7 billion and then to about $850 million as software deal activity dried up. If commitments fell again, the leverage ramp stalls and $0.32 starts to look optimistic. A rebound, even a modest one, alongside leverage near the middle of the range, would support management's argument that earnings can climb without a big recovery in deal flow.

Pricing is the second lever. Management said software spreads are roughly 150 to 200 basis points wider than early-2025 lows and pointed to about $4.7 billion of older loans priced below SOFR plus 500 that could reset higher over time. This quarter should show whether that is actually happening. A rising weighted average yield on new loans, or early repricing of legacy loans, would be real evidence. A flat portfolio yield would suggest the opportunity is slower than advertised. Diversification also bears watching, particularly whether the Caris life sciences loan and the digital infrastructure pipeline grow from their current small share of the book.

Credit is where the stock's discount gets tested most directly. Non-accruals were just 10 basis points of fair value in June, among the lowest in the industry, and weaker-rated names fell to 7.6% from 8.5%. One small new non-accrual was added last quarter, so another addition would draw attention. PIK income eased to about 12.5% of investment income, and a further decline would signal healthier borrower cash flow. NAV is the key number. After stabilizing near $16.48, any drop would revive the software valuation concerns that hit the first quarter, while a small gain would strengthen the case that the worst is over. Potential gains from selling the remaining SpaceX stake could also give NAV a lift if they materialize.

Sentiment has soured, with the bearish reading rising to 49.7% from 40.3% before the last report, and the stock is trading near the bottom of its post-earnings range of $8.76 to $11.82, well under its 200-day average of $11.24. Expectations are low, but so is patience. Buybacks, with about $195 million left on the authorization, may help at these prices. The real question is whether the company can show a credible, steady climb toward full dividend coverage through higher leverage, wider spreads and clean credit. If it can, the gap with NAV looks excessive. If origination stays weak or NAV slips, the market's skepticism will look justified.